Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Eli Lilly & Co. (LLY), GlaxoSmithKline plc (ADR) (GSK), And Why You Don’t Have to Run a Cartel to Make Big Profits in Drugs

Good businesses, highly valued

Investing in stocks is about more than just finding good businesses–that is only half of the equation. The price at which we buy an investment is instrumental in determining our ultimate profit.

Eli Lilly & Co. (NYSE:LLY) and Pfizer Inc. (NYSE:PFE) are excellent examples of good businesses that are well run but simply priced too high at the current time to justify investment with a realistic expectation of double digit returns over an extended period of time. Both carry high payout ratios to support the existing dividends, and the projected earnings growths rates for both could best be described as modest.

These are both large, stable businesses but investors in either should be willing to accept total returns between 5% and 8% a year over the long term. While those are not horrible numbers when compared to government bonds or interest on savings, it is not what I am willing to accept when taking on the risk of stocks.

Roll the dice on a one-trick pony

Those wishing to take on a larger risk with an inexpensive drug stock with only one product might wish to take a close look at Questcor Pharmaceuticals Inc (NASDAQ:QCOR). It’s one product is H.P. Acthar gel. The stock was hammered last fall due to concerns surrounding insurance reimbursements for off-label uses. Those concerns now appear to have been overblown, and a more detailed discussion of the business can be found here. Questcor Pharmaceuticals Inc (NASDAQ:QCOR) is scheduled to report earnings on April 30, and I expect the stock to move higher on strong results.

Final Foolish thoughts

Investors seeking relative safety and out-sized performance should consider investing in Abbott Laboratories (NYSE:ABT) and GlaxoSmithKline plc (ADR) (NYSE:GSK). Those with a gambler’s soul may wish to consider a position in Questcor Pharmaceuticals Inc (NASDAQ:QCOR) in front of the next earnings report.

The article You Don’t Have to Run a Cartel to Make Big Profits in Drugs originally appeared on Fool.com.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.